Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $56,576.60 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total transaction of $56,576.60. Following the transaction, the vice president directly owned 40,411 shares in the company, valued at approximately $3,693,565.40. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Down 0.8%

EW traded down $0.71 during trading on Tuesday, hitting $90.47. 3,609,561 shares of the company’s stock were exchanged, compared to its average volume of 4,861,138. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $92.88. The stock has a 50 day moving average price of $84.66 and a 200 day moving average price of $83.31. The firm has a market cap of $52.09 billion, a P/E ratio of 48.12, a price-to-earnings-growth ratio of 2.29 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EW. Evercore restated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Robert W. Baird increased their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $96.39.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently made changes to their positions in EW. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences in the first quarter valued at $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.